Fahimtar dangantaka tsakanin MRD da CAR T-Cell far
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Mesenchymal stem cell far a cikin cututtuka na jijiyoyin jini
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
FDA ta ba da sunayen magungunan marayu ga CART T-Cell Therapy A2B530 don maganin ciwon daji na colorectal
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Iovance's Amtagvi ya amince da USFDA a matsayin farkon maganin T-cell don ƙaƙƙarfan ƙwayar cuta.
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Amivantamab-vmjw an amince da USFDA don EGFR exon 20 alamun cutar kansar huhun da ba ƙananan ƙwayoyin cuta ba.
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Osimertinib tare da chemotherapy an amince da su ta USFDA don EGFR-mutated non-saramin cell cancer.
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Lifileucel ta amince da USFDA don rashin ganowa ko melanoma mai tsauri
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
USFDA ta amince da Tepotinib don ciwon huhu mara ƙananan ƙwayar cuta
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Irinotecan liposome ya amince da USFDA don maganin layin farko na adenocarcinoma na pancreatic.
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
USFDA ta amince da Erdafitinib don ci-gaban gida ko ciwon daji na urothelial metastatic
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..